1. Home
  2. IDAI vs OGEN Comparison

IDAI vs OGEN Comparison

Compare IDAI & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IDAI
  • OGEN
  • Stock Information
  • Founded
  • IDAI 2016
  • OGEN 1996
  • Country
  • IDAI United States
  • OGEN United States
  • Employees
  • IDAI N/A
  • OGEN N/A
  • Industry
  • IDAI Computer Software: Prepackaged Software
  • OGEN Biotechnology: Pharmaceutical Preparations
  • Sector
  • IDAI Technology
  • OGEN Health Care
  • Exchange
  • IDAI Nasdaq
  • OGEN Nasdaq
  • Market Cap
  • IDAI 5.0M
  • OGEN 4.6M
  • IPO Year
  • IDAI N/A
  • OGEN N/A
  • Fundamental
  • Price
  • IDAI $2.04
  • OGEN $4.28
  • Analyst Decision
  • IDAI
  • OGEN
  • Analyst Count
  • IDAI 0
  • OGEN 0
  • Target Price
  • IDAI N/A
  • OGEN N/A
  • AVG Volume (30 Days)
  • IDAI 46.6K
  • OGEN 599.0K
  • Earning Date
  • IDAI 05-15-2025
  • OGEN 05-09-2025
  • Dividend Yield
  • IDAI N/A
  • OGEN N/A
  • EPS Growth
  • IDAI N/A
  • OGEN N/A
  • EPS
  • IDAI N/A
  • OGEN N/A
  • Revenue
  • IDAI $3,054,143.00
  • OGEN N/A
  • Revenue This Year
  • IDAI $65.46
  • OGEN N/A
  • Revenue Next Year
  • IDAI $12.00
  • OGEN N/A
  • P/E Ratio
  • IDAI N/A
  • OGEN N/A
  • Revenue Growth
  • IDAI N/A
  • OGEN N/A
  • 52 Week Low
  • IDAI $1.43
  • OGEN $3.12
  • 52 Week High
  • IDAI $18.75
  • OGEN $75.60
  • Technical
  • Relative Strength Index (RSI)
  • IDAI 44.42
  • OGEN 43.10
  • Support Level
  • IDAI $2.05
  • OGEN $3.12
  • Resistance Level
  • IDAI $2.32
  • OGEN $9.60
  • Average True Range (ATR)
  • IDAI 0.15
  • OGEN 1.04
  • MACD
  • IDAI -0.02
  • OGEN -0.12
  • Stochastic Oscillator
  • IDAI 9.01
  • OGEN 17.90

About IDAI T Stamp Inc.

T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.

About OGEN Oragenics Inc.

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.

Share on Social Networks: